In conclusion, the majority of patients with BPDCN have somatic mutations involving epigenetic regulators and RNA splicing factors, in addition to ETV6 and IKZF1, which are also frequently mutated. This evidence concerns the gene IKZF1 and CD4+/CD56+ hematodermic neoplasm.